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Abstract 
Differential MS analysis of blood samples from diseased and control subjects is increasingly 
being employed in the hunt for biomarkers that can detect disease at an early stage.  For 
diagnostic tests, in particular for population screening, robust protocols are required that can 
offer high-throughput analysis, ideally at high mass spectrometric sensitivity.  To achieve 
this, blood samples need to be collected, prepared and analyzed in a standardized manner that 
minimizes potential bias.  Simple purification methods combined with MALDI MS profiling 
have so far been championed for providing the best approach. 
In this chapter, we describe an adapted and validated protocol based on a simple and fast 
solid-phase extraction technique using ZipTips®.  This protocol facilitates the purification of 
potential blood biomarkers in a few steps for mass spectral biomarker pattern diagnostics 
using MALDI.  It is suitable for use in an automated high-throughput and potentially clinical 
environment and has the advantage of only requiring a few microlitres of blood plasma or 
serum.  The presented protocol has been tested over several years in our laboratory and found 
to be more reproducible and suitable for plasma and serum profiling than similar 
methodologies based on magnetic bead purification. 
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1. Introduction 
The ultimate goal of biomarker research is to establish straightforward, cost-effective, 
minimally invasive clinical tests with high sensitivity and specificity for early disease 
detection.  Profiling blood and blood-derived products based on mass spectrometry (MS) is 
becoming a powerful tool to mine the physiologically informative molecules contained in this 
biofluid 1-3.  By its nature and availability, blood has the potential to be an ideal medium for 
elucidating the current state of health.  During the last few years many studies, using matrix-
assisted laser desorption/ionization (MALDI) time-of-flight (TOF) MS coupled with 
bioinformatics tools, have been reported as being capable of distinguishing between the 
polypeptide patterns of healthy individuals and patients diagnosed with various diseases 1, 4-6.  
However, none of the biomarkers identified in these studies have so far been progressed 
towards their clinical use 7, 8. 
One of the major obstacles for the direct discovery of new biomarkers in blood is due to its 
complexity, which includes the presence of salts, lipids, and other biological matrix 
compounds and the high dynamic range of proteins, making it extremely difficult to detect 
and analyze disease-specific biomarkers by MS.  For example, when untreated plasma or 
serum is analyzed on a standard MALDI target plate, it does not produce any useful spectra.  
Thus, to overcome these obstacles there is an obvious need for improved methods to facilitate 
MALDI MS analysis of blood without losing its diagnostic power.  Any such method needs 
to be employable across many different laboratories and to incorporate high standards and 
quality control throughout the entire analytical workflow including sample collection, 
preparation, MS analysis, and data processing and mining 9-11. 
As a consequence, detailed studies have been reported with the aim of standardizing 
protocols and reducing systematic biases.  Indeed, it has been shown that many non-
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biological variations can be introduced during blood sample collection, preparation, and 
storage, adding to possible deficiencies in study design and inappropriate data analysis 
approaches 3, 12-14.  Some of the resulting standardized protocols are now used with more 
confidence in discovering and validating new biomarkers with the hope of reducing the gap 
between the discovery of MS-based candidate biomarkers and their clinical application. 
The protocol described in this chapter has been developed and refined over a period of more 
than five years, in particular for the analysis of blood serum.  It has emerged from extensive 
tests that have been undertaken in order to establish a high-throughput protocol that provides 
both precise and accurate measurements.  The protocol is based on MALDI-TOF MS 
profiling of blood samples that are purified employing commercial ZipTip® technology.  As 
such it is a simple and robust method for providing mass spectral patterns that can be used for 
sample classification and, thus, potentially for clinical diagnostics and early disease detection. 
The overall workflow (see Figure 1) is composed of three main steps which are (i) sample 
collection, (ii) sample preparation and analyte purification, and (iii) MS data acquisition and 
analysis.  It is suitable for both manual and automated sample preparations and analyses 14.  
The automated sample preparation procedures have been developed in our laboratory based 
on an easy-to-operate and cost-effective robotic platform, a CyBi®-disk robot (CyBio AG, 
Jena, Germany) equipped with a 96-piston head and modified for the use of ZipTips®.  The 
time needed for the robotic preparation of up to 90 samples is only about 30 minutes.  The 
emphasis of this protocol is on the collection of high-quality data, which can then optionally 
be combined with other biomarker data or metadata and processed using a number of 
different complex statistical techniques and bioinformatics.  In principle, the MALDI MS 
profile data files typically undergo a series of data pre-processing steps (e.g. baseline 
subtraction, smoothing, alignment) before being subjected to various classification and test 
methods to identify biomarkers (that are differentially expressed in disease), which are in turn 
5 
 
tested either alone or in combination with additional biomarkers (and/or other data) to 
determine their diagnostic accuracy.  Due to the vast variety and complexity of the 
approaches possible in this field, data processing and mining is beyond the scope of this 
protocol. 
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2. Materials 
2.1. Blood collection and preparation (in clinical lab) 
1. Blood collection tubes (see Note 1): 
- For plasma preparation:  Tubes containing an anti-coagulant, such as Vacutainer 
PST tubes (BD, Franklin Lakes, NJ, USA, cat. no. 367960) or S-Monovette® 
tubes (Sarstedt, Newton, NC, USA, cat. no. 02.1065) for up to seven mL of blood 
or Microvette® tubes (Sarstedt, cat. no. 20.1309) for volumes up to 300 µL. 
- For serum preparation:  Vacutainer SST tubes (BD, cat. no. 367988) or S-
Monovette® tubes (Sarstedt, cat. no. 02.1063) for up to seven mL of blood or 
Microvette® tubes (Sarstedt, cat. no. 20.1308) for volumes up to 300 µL. 
2. Chilled centrifuge capable of spinning blood collection tubes at 13,000 g. 
3. Cryovials (e.g. cryostraws) and cryoboxes for sample storage (Fisher Scientific, 
Loughborough, UK, cat. no. FB71035). 
4. Natural microcentrifuge tubes:  0.2 mL and 1.5 mL (Bioquote, York, UK, cat. nos. 
BA4300F and 16130). 
2.2. Sample pre-processing and sub-sampling (in clinical or MS lab) 
1. Standard plasma or serum (see Note 2). 
2. Cryoboxes for sample storage (Fisher Scientific, cat. no. FB71035). 
3. Natural microcentrifuge tubes:  0.2 mL and 1.5 mL (Bioquote, cat. nos. BA4300F 
and 16130). 
4. 96-well microtitre plates with lids (Fisher Scientific, cat. no. TUL-962-060A). 
5. Low-profile Thermostrips (ABgene, Epson, UK, cat. no. AB0773). 
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6. Virkon® disinfection solution (Fisher Scientific, cat. no. HYG-205-030J). See Note 3 
for solution preparation. 
2.3. Analyte extraction, purification and analysis (in MS lab) 
1. Acidification solution (2% TFA, pH ≈ 0.5). 
2. Equilibration and washing solution (0.1% TFA, pH ≈ 2). 
3. Elution solution (50% ACN/0.1% TFA). 
4. α-cyano-4-hydroxycinnamic acid (CHCA) (Bruker Daltonics, Bremen, Germany, 
cat. no. 201344). 
5. Standard plasma or serum (same as in the previous section). 
6. Protein and peptide MS calibration standards (Bruker Daltonics, cat. nos. 206355 
and 222570). 
7. C18 ZipTips® (Millipore, supplied by Fisher Scientific, cat. no. FDR-597-040G). 
8. Natural microcentrifuge tubes:  0.2 mL and 1.5mL (Bioquote, cat. nos. BA4300F 
and 16130). 
9. 96-well microtitre plates (Fisher Scientific, cat. no. TUL-962-060A). 
10. 30 mL-Teflon® bottle (Fisher Scientific, cat. no. BTK-260-010V). 
11. pH 0-6 indicator sticks (Fisher Scientific, cat. no. FB33005). 
12. Isofreeze PCR rack (Alpha-Laboratories, Eastleigh, UK, cat. no. LW5990Y). 
13. AnchorChip-600 384-spot MALDI target plates (Bruker Daltonics, cat. no.209513). 
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3. Methods 
Users of this protocol should have read and understood all relevant Risk Assessments and 
Health and Safety rules and regulations and SOPs for the handling of blood and blood-
derived samples before starting any work. 
The various procedures detailed in the following protocol can be grouped into four 
independent steps: 
(i) Phlebotomy and plasma/serum generation and separation which usually occur in 
clinical laboratories or health care centres. 
(ii) Sub-sampling the plasma/serum samples which can be performed either 
immediately after blood collection at the collection site or later in the MS 
laboratory.  At the end of this step small, ready-to-analyse sample volumes are 
stored in microtitre plates. 
(iii) Purification of analytes (mainly polypeptides) from plasma/serum:  This part of 
the protocol is critical and involves binding the analytes to a chromatographic 
phase followed by a washing step at which non-bound compounds are removed.  
The analytes are then eluted off the chromatographic support before being mixed 
with the matrix and spotted onto a MALDI target plate.  This step is carried out in 
the MS laboratory (see Figure 2). 
(iv) MS data acquisition and analysis:  This last step consists of collecting MALDI 
mass spectra under strict QC procedures from the samples prepared above (see 
Figure 2).  The obtained data are then analyzed using appropriate software and 
bioinformatics tools. 
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3.1. Collecting blood samples and preparing plasma/serum 
1. Collect blood in the appropriate tube (either for plasma or serum) and label it with 
the corresponding sample details.  Gently mix the blood by inverting the tube 10 
times (see Note 4).  The following steps are suitable for blood volumes between 
tens of microlitres and tens of millilitres.  For other amounts of blood, this protocol 
(including consumables and equipment) might need to be adjusted. 
2. (a) For plasma preparation: 
- Centrifuge the blood sample at 13,000 g for 5 min at 4°C. 
- Decant the plasma (top layer) to appropriately sized and labelled cryovials, 
taking care not to disturb the middle whitish layer (mononuclear cells and 
platelets) or the bottom layer (red blood cells). 
(b) For serum preparation: 
- Allow blood to clot for 1 h at room temperature keeping the tube in the upright 
position (see Note 5). 
- Spin tubes at 1,400 g for 10 min at room temperature. 
- Transfer the serum (upper phase) to appropriately sized and labelled cryovials.  
If resources (time, staff and sample storage) allow, as many aliquots of the 
appropriate volume as possible should be made in order to minimize freeze-
thaw cycles. 
3. Immediately store all samples at –80°C. 
4. Transport samples to the MS laboratory on dry ice.  On arrival they must be 
immediately stored at –80°C (see Note 6). 
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3.2. Pre-processing and sub-sampling of plasma/serum samples 
This protocol assumes that plasma or serum samples will be sub-sampled into microtitre 
plates before the analyte extraction procedure.  The following steps detail this procedure 
(see Note 7). 
1. Remove the sample tubes from the freezer, and allow the samples to thaw on an ice-
bath (see Note 8). 
2. Randomize samples before any further steps are taken to avoid any systematic error 
due to the sample order or history. 
3. Transfer the samples from cryostraws to microcentrifuge tubes (this step is only 
necessary when cryostraws are used such as for long-term, large-scale sample 
storage): 
- Remove the first straw from the freezer and scan the barcode on the straw or, if no 
bar codes are used, write down the sample details. 
- Using scissors, cut the straw just below the closure at the top. 
- Invert the straw and place the cut end in a 1.5 mL-tube.  Now cut the other end of 
the straw and dispose of the cut-off pieces in the Virkon® solution.  Wash the 
scissor blades with ethanol. 
- Lift the straw slightly to allow the thawed serum to drain into the tube.  Use the 
pipettor with a tip attached to blow air through the straw from the top down, in 
order to expel the last few drops of plasma/serum into the tube.  Place the empty 
straw into the Virkon® solution.  Use the pipettor with the same tip still attached to 
mix the content of the tube, ensuring that the whole sample is thoroughly thawed 
and homogeneous. 
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4. Sub-sampling from microcentrifuge tubes to microtitre plates: 
- Transfer 5 µL of plasma/serum to the corresponding well in one or more 
microtitre plates as required, leaving on each microtitre plate 6 wells vacant for 
the use of control samples as detailed later (see Note 9).  Record the position of 
each sample on a microtitre plate plan (see Note 10). 
- From the remaining volume sub-sample as many aliquots as required into 200 µL-
tubes or thermostrips (these can be later used for single point analysis). 
- Pipette 5 µL-aliquots of the standard plasma/serum sample (thawed and 
homogenized) to 3 of the 6 empty wells on the microtitre plates containing 
samples and record their position on the microtitre plate plans.  This standard 
sample will be used as initial control for the whole run.  The 3 remaining empty 
wells are later used for post-preparation control samples (see SST solution, section 
3.3.1). 
5. Cover each microtitre plate with a cover lid and secure the lid in place with a rubber 
band.  Put each plate inside a small clear plastic bag, and place the bags together 
with a copy of the plate plan in a labelled sample box. 
6. Immediately freeze the samples and store them at -80°C until required. 
 
 
3.3. Extracting analytes from plasma/serum samples 
This protocol describes the manual extraction of mainly polypeptidic analytes from blood 
plasma/serum which is suitable if the number of samples is just a few.  It requires the samples 
to be in a microtitre plate format suitable for the use of an eight-channel pipettor.  However, 
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this protocol can also be applied using single tubes but needs to be adjusted accordingly.  For 
large sample sets and high throughput extraction a liquid handling robot is recommended. 
 
3.3.1. Preparation of solutions (see Note 11) 
1. Matrix solution (0.5 mg/mL CHCA in ethanol:acetone; 2:1):  Add 1 mL of acetone to 
an 1.5 mL-tube containing 3 mg of CHCA and vortex until the CHCA is dissolved.  
Add 4 mL ethanol and 1 mL acetone to a 30 mL-Teflon® bottle, then add the CHCA 
solution to give a total volume of 6 mL.  Mix the solution and keep at 4°C in the dark 
until needed. 
2. Polypeptide Calibrant Standard (PCS) solution:  Add 125 µL of the 0.1% TFA 
solution to a vial of peptide calibration standard (see Materials for details) and 
vortex thoroughly to solubilize the peptides.  Do the same with a second vial for the 
protein calibration standard (see Materials for details).  Transfer 25 µL from the first 
vial to a 1.5 mL-tube and add all the contents of the second vial plus 600 µL of 0.1% 
TFA.  Mix and aliquot at 4 µL.  Store the aliquots at -20°C (see Table 1 for a list of 
PCS components). 
3. System Suitability Test (SST) solution:  A 96-well plate containing 5 µL of the 
standard plasma/serum in each well is prepared in advance using the steps detailed 
in section 3.3.2. (steps 1.-4.; see below).  Sample eluates are pooled, mixed and then 
aliquotted at 4 µL.  Aliquots are stored at -80 °C until required (see Note 12). 
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3.3.2. Sample clean-up and MALDI sample preparation 
1. Preparing the samples 
- Remove the aliquotted samples from the freezer and thaw them on an Isofreeze PCR 
rack keeping their temperature at no more than 4°C. 
- Immediately after thawing, add 5 µL of 2% TFA to each sample well and 
aspirate/dispense several times to ensure good mixing. 
2. Preparing the ZipTips® (see Note 13). 
- Load 8 ZipTips® onto a multi-channel pipettor. 
- Aspirate 10 µL of ACN onto each ZipTip® and dispense it to waste.  Repeat twice. 
- Aspirate 10 µl of 0.1 % TFA onto each ZipTip® and dispense it to waste.  Repeat 
twice. 
3. Binding and washing the analytes 
- Slowly aspirate and dispense the sample solutions back into the same well.  Repeat 9 
times. 
- Aspirate 10 µL of 0.1 % TFA onto each ZipTip® and dispense it to waste (or collect if 
the washing fractions are to be analysed).  Repeat twice.  
4. Eluting the samples 
- Elute the analytes bound to each ZipTip® with 7 μL of 50 % ACN / 0.1 % TFA by 
aspirating/dispensing the eluent 5 times through the ZipTips® into the wells of a new 
microtitre plate and keep it on the Isofreeze PCR rack. 
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5. Mixing the eluates with the matrix 
- Transfer 18 µL of matrix solution into the wells of a new microtitre plate. 
- Add 2 µL of each eluate to the 18 µL of matrix solution.  Aspirate/dispense at least 5 
times to mix. 
- Immediately spot 0.8 µL of the mixtures onto the anchors of the MALDI target.  Spot 
each eluate 4 times, leaving 12 random anchors vacant for SST samples (see Notes 12 
and 14). 
 
6. MALDI calibrant and control sample preparation 
- Transfer 27 µL of the matrix solution to two 200 µL-tubes and close the lids tightly.  
Take a 4 µL-aliquot of each of the SST and PCS solutions from the freezer and let 
them thaw at room temperature. 
- Vortex the PCS solution and add a 3 µL-aliquot of it to one of the tubes containing 
matrix solution, and vortex/mix thoroughly.  Spot 0.8 µL of this mixture onto each of 
10 random calibrant positions on the MALDI target plate.  These spots are used for 
external calibration.  The amount of each polypeptide spotted is ca. 10 fmol for 
peptides and ca. 50 fmol for proteins. 
- Vortex the SST solution and add a 3 µL-aliquot of it to the other tube containing 
matrix solution, and vortex/mix thoroughly.  Spot 0.8 µL of this mixture onto their 
allocated positions (12 per MALDI target plate, see Note 9).  These spots will be used 
to assess the performance of the MALDI sample preparation and MS analysis (see 
details below in section 3.4.2). 
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- Wait until all MALDI sample spots are completely dry (see Note 14). 
 
3.4. MALDI MS data acquisition and analysis 
3.4.1. Data acquisition 
This protocol describes a typical workflow employing an Ultraflex II MALDI-
TOF/TOF instrument (Bruker Daltonics) in the linear positive ion mode controlled by 
the FlexControl software v.3.0 with samples spotted on AnchorChip target plates 
having 384 anchors of 600 µm diameter. 
1. Open the FlexControl software and load optimised FlexControl and AutoXecute 
methods (see Table 2 and Note 15).  These settings must be optimised for each 
individual instrument. 
2. Insert the MALDI target plate into the mass spectrometer.  The plate should be 
analysed within 2 hours of MALDI sample spotting. 
3. Calibrate the mass spectrometer using a single calibrant sample spot containing the 
PCS mixture (see Note 16).  Data should be collected automatically by clicking on 
the tab “Run method on current spot”. 
4. Collect spectra from an SST sample spot to check that shots are accumulated and the 
AutoXecute evaluation criteria are met (see Note 17 and Figure 2).  If this is not the 
case, re-adjust the laser power accordingly and collect spectra from another SST 
spot to fulfil these conditions.  Data should be collected automatically by clicking on 
the Tab “Run method on current spot”.  A typical mass spectrum obtained from a 
pooled human serum sample is shown in Figure 3. 
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5. Load the correct autoXsequence file (containing the names and positions of each 
sample on the target as well as the file name and path where the spectra will be 
saved on the hard disk).  This file can be generated by using the spreadsheet from 
the sample plate plan initially prepared. 
6. Start the automatic run by clicking on the tab “Start automatic run”.  Data collection 
for a full 384-spot plate (spotted from a full 96-well microtitre plate) takes about 6 
hours. 
 
3.4.2. Data quality control and filtering/processing 
In the following steps FlexAnalysis 3.0 and ClinProTools 2.1 software (Bruker 
Daltonics) are used. 
1. Within the FlexAnalysis program, open the folder containing all the acquired spectra 
by choosing the “Process” menu, then selecting “Batch check” and clicking on 
“Folder”.  Within the next window click on “Browse” and select the batch of sample 
data folders.  Click on “Start Batch Check” and set the expected number of shots to 
1,000.  By clicking “OK” this will generate a report detailing the spectra with less 
than 1,000 shots which should then be excluded from further processing. 
2. Within the ClinProTools program, load the spectra files of the SST samples by 
selecting “Open Model Generation Class” under the “File” menu.  View the spectra 
in the pseudo-gel view. 
3. Load the spectra of the standard plasma/serum samples, which will be depicted in 
the pseudo-gel view alongside the spectra of the SST samples.  The 2 classes should 
give virtually identical spectra, in which case the overall preparation of the batch of 
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samples is deemed acceptable.  If the spectra are markedly different or two or more 
spectra per sample have been excluded further investigation will be needed to 
determine the cause. 
4. Load the spectra of each individual sample as a class into ClinProTools, and inspect 
them visually to determine any obvious differences within that class.  If differences 
are found it may be necessary to exclude the entire data set for this sample on the 
basis of poor quality (see Note 18). 
3.4.3. Preliminary Data Analysis 
Curated spectra sets can be analysed using ClinProTools or exported from 
FlexAnalysis as tab-separated 2-column text files that contain the mass list with the 
corresponding intensities for use with other software packages for more detailed 
analysis of the data.  For instance, ClinProTools can be used to determine peaks that 
are significantly different (in intensity or area) between 2 or more classes of spectra, 
by using the average spectra and clustering feature.  It is also possible to use this 
program to generate other classification models (for example, Genetic Algorithms, 
Support Vector Machine) based on lists of discriminatory peaks.  However, this 
higher level of data analysis and data mining is beyond the scope of this protocol. 
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4. Notes 
1. Recommendations vary for the best anti-coagulant and whether to use plasma or 
serum 15.  For plasma analysis, this protocol has been developed using small mouse 
blood volumes collected with microvette® tubes (Sarstedt, Newton, NC, USA, cat. 
no. 20.1309) containing heparin as anti-coagulant.  For serum analysis, this protocol 
has been developed using human serum obtained from blood collected with 
Vacutainer SST tubes (BD, USA, Franklin Lakes, NJ, cat. no. 367988). 
2. For plasma analysis, this protocol has been developed with commercial standard 
mice plasma from C57BL6 mice (Patricell, Nottingham, UK, cat. no. IMS-C57BL6-
N-12).  For serum analysis, this protocol has been developed with commercial 
standard human serum (Sigma-Aldrich, Dorset, UK, cat. no. S7023). 
3. Virkon® solution:  Add 10 g of Virkon® powder to one litre of water.  Mix 
thoroughly until completely dissolved, resulting in a pink coloured solution.  Replace 
the solution when the pink colour has gone (about one week). 
4. When collecting blood samples, a proper phlebotomy technique should be applied.  
Ideally, the same amount of blodd is collected for each sample.  Haemolysis should 
be avoided at this step as well as any other (subsequent) steps. 
5. Blood should be allowed to clot for exactly 1 hour, otherwise differences in the mass 
spectral profiles might arise due to different clotting times of the samples. 
6. Avoid freeze-thaw cycles at all steps because they induce proteolysis (in the absence 
of anti-proteases) and the precipitation of peptides/proteins. 
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7. All sub-sampling must be carried out in an adequate safety cabinet.  Equipment and 
consumables used for the purpose of sub-sampling should be housed inside the 
cabinet and should be labelled with biohazard labels (tubes, pipette tips, solutions, 
etc.).  Before starting work, ensure that there are two 1-litre Virkon® solutions 
available that are less than one week old and still pink.  One of the solutions should 
be placed in a wide-mouthed screw cap jar for disposal of plastic consumables, and 
the other should be in a screw cap bottle for dealing with accidental spills. 
8. The amount of time that individual samples are outside of the -80°C freezer must be 
kept to a minimum.  All sample vials, tubes and plates must be kept on wet ice or 
Isofreeze PCR racks during the entire sub-sampling procedure.  Standard 
plasma/serum samples should be initially aliquotted at 200 and 500 µL into 500-µL 
tubes and stored at -80 °C until required. 
9. The sample volume available determines the number of replicates that can be 
prepared as 5 µL is needed for each preparation.  All samples with a total volume of 
less than 5 µL should be excluded.  It is preferable to prepare each sample at least 3 
times.  However, if this is not possible then for each individual sample as many 
replicates as possible should be made.  Each 96-well microtitre plate is used for up to 
90 sample aliquots to be run manually or on a liquid handling robot.  The remaining 
6 wells are vacant for the use of control samples as detailed later.  Briefly, 3 vacant 
wells will be filled with standard plasma/serum samples that will provide controls for 
the entire sample preparation workflow.  The other 3 vacant wells will remain empty 
in case the microtitre plate is used in an automated workflow.  From these wells no 
samples will be prepared or spotted on the respective MALDI target plate positions, 
which then can be used for the preparation of SST samples (see Note 12). 
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10. In an automated workflow for large sample sets, the sub-sampling procedure can be 
carried out in two steps.  First from tubes into parent microtitre plates, then from 
parent to child (replicate) microtitre plates.  For example, in our lab we use a liquid 
handling CyBi®-Disk robot (CyBio AG) equipped with a 96-piston head for 25 µL-
tips and 10 microtitre plate positions, specifically set-up for this task. 
11. The matrix solution should be freshly prepared on the day of the experiment.  The 
solutions of 2% TFA, 0.1% TFA and 50% ACN/0.1% TFA should be replaced 
weekly.   
12. SST solutions/samples are used as controls to check both the performance of the 
mass spectrometer and the quality of the MALDI sample preparation. 
13. Ensure that ZipTips® do not dry out or aspirate air during the entire procedure. 
14. Ensure that the relative humidity in the lab is between 35–60% during MALDI 
sample preparation (incl. crystallisation).  Very low or very high humidity 
dramatically affects the crystallization and thus, the MALDI MS ion signal. 
15. Data acquisition should be automated.  In this protocol, an automated workflow is 
provided for an Ultraflex II TOF/TOF instrument using the instrument’s 
‘AutoXecute’ function.  Each spectrum is the sum of 1,000 single laser shots 
randomized over 10 positions within the same spot (100 shots/position) at a laser 
frequency of 25 Hz.  Before each acquisition cycle of 100 laser shots, the new 
position on the target spot is pre-irradiated with 10 laser shots at 10% higher laser 
power to improve spectral quality.  Evaluation parameters are set so that only spectra 
(of 100 shots) containing at least one peak with a resolving power of greater than 300 
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and a signal-to-noise ratio of more than 10 in the m/z range of 700-10,000 are 
accumulated. 
16. The calibration can be checked on a second PCS spot and repeated if necessary. 
17. Prior to analyzing an entire MALDI target, an SST sample spot should be used for 
adjusting the laser power and as a general system check.  Using this control sample, 
the resolution and intensity of five major peaks across the mass range 1,800 to 8,200 
Da are typically checked against previously obtained data.  If necessary, the laser 
energy is adjusted to keep the intensity and resolution of these peaks within a range 
of ± 2 standard deviations.  In addition, the overall performance of the mass 
spectrometer should be thoroughly checked every 2-3 weeks using peptide standards. 
18. If the number of replicate spectra per sample falls below 3 as a result of spectra 
exclusion, it may be necessary to repeat the sample preparation, if this is possible. 
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Table 1.  Polypeptide calibrant list used for external calibration 
 
Polypeptide  Ion type Average mass 
m/z 
Peptide calibration standard II mixture  
(Bruker Daltonics, #222570) 
  
Bradykinin Fragment 1‐7 [M+H]+ 757.858 
Angiotensin II [M+H]+ 1047.189 
Angiotensin I [M+H]+ 1297.486 
Substance P  [M+H]+ 1348.642 
Bombesin  [M+H]+ 1620.860 
Renin Substrate Tetradecapeptide Porcine [M+H]+ 1760.026 
ACTH clip 1‐17 [M+H]+ 2094.427 
ACTH clip 18‐39  [M+H]+ 2466.681 
Somatostatin 28  [M+H]+ 3149.574 
Protein calibration standard I mixture  
(Bruker Daltonics, #206355) 
  
Insulin  [M+H]+ 5734.56 
Ubiquitin I  [M+2H]2+ 4283.45 
Cytochrome C  [M+2H]2+ 6181.05 
Ubiquitin I  [M+H]+ 8565.89 
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Table 2.  Ultraflex instrument settings optimized for the analysis of LMW plasma/serum 
analytes, using FlexControl software v3.0 
Parameters  Values 
Laser source Nitrogen (337nm) 
Digitizer  2 GHz 
Mass range for data acquisition  700 -10,000 Da 
Acquisition mode Linear, positive ions 
Ion acceleration  25 kV 
Delayed extraction potential difference  1.6 kV 
Lens potential  6 kV 
Gating strength for matrix suppression High (for ions <400Da) 
Delayed extraction 100 ns 
Detector gain 7.5 
Sample rate 0.5 GS/s 
Data points per spectrum 32,163 
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Figure Captions 
Figure 1.  Workflow showing the major steps required for MS profiling and biomarker 
discovery from blood. 
 
Figure 2.  Workflow diagram showing the various steps of plasma/serum sample preparation 
using ZipTips®and quality control before MS data acquisition. 
 
Figure 3.  MALDI-TOF MS profile of a pooled human blood serum sample obtained from 
purification of a 5 μL-aliquot using 18-ZipTips®.  The mass spectrum was generated by 
ClinProTools software (V2.1) after baseline-subtraction, smoothing and normalization. 
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